<DOC>
	<DOCNO>NCT01839916</DOCNO>
	<brief_summary>This pilot phase II trial study well give donor T cell donor stem cell transplant work treat patient hematologic malignancy . In donor stem cell transplant , donated stem cell may replace patient 's immune cell help destroy remain cancer cell ( graft-versus-tumor effect ) . Giving infusion donor 's T cell ( donor lymphocyte infusion ) transplant may help increase effect .</brief_summary>
	<brief_title>Donor T Cells After Donor Stem Cell Transplant Treating Patients With Hematologic Malignancies</brief_title>
	<detailed_description>PRIMARY OBJECTIVES : I . To determine feasibility escalate dose regimen ( EDR ) donor lymphocyte infusion ( DLI ) measure proportion patient receive least one DLI . SECONDARY OBJECTIVES : I . To assess progression free survival ( PFS ) 2 year stem cell transplant ( SCT ) high-risk hematologic malignancy receive T-cell deplete graft follow escalate dose regimen ( EDR ) prophylactic DLI compare historical control receive DLI . II . To assess safety EDR DLI high-risk hematologic malignancy measure cumulative incidence severe grade III-IV acute graft-versus-host disease ( GVHD ) . III . To measure outcomes grade II-IV acute GVHD , non-relapse mortality , overall survival chronic GVHD EDR DLI . IV . To assess full donor chimerism rate CD3 compartment immune reconstitution EDR DLI . OUTLINE : Patients receive DLI intravenously ( IV ) . Treatment repeat every 4-8 week 5 dos absence disease progression unacceptable toxicity . After completion study treatment , patient follow periodically 2 year .</detailed_description>
	<mesh_term>Lymphoma</mesh_term>
	<mesh_term>Syndrome</mesh_term>
	<mesh_term>Leukemia</mesh_term>
	<mesh_term>Leukemia , Myeloid</mesh_term>
	<mesh_term>Leukemia , Myeloid , Acute</mesh_term>
	<mesh_term>Lymphoma , Follicular</mesh_term>
	<mesh_term>Lymphoma , Non-Hodgkin</mesh_term>
	<mesh_term>Myelodysplastic Syndromes</mesh_term>
	<mesh_term>Preleukemia</mesh_term>
	<mesh_term>Leukemia , Lymphoid</mesh_term>
	<mesh_term>Leukemia , Lymphocytic , Chronic , B-Cell</mesh_term>
	<mesh_term>Precursor Cell Lymphoblastic Leukemia-Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large B-Cell , Diffuse</mesh_term>
	<mesh_term>Burkitt Lymphoma</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Immunoblastic</mesh_term>
	<mesh_term>Plasmablastic Lymphoma</mesh_term>
	<mesh_term>Lymphoma , T-Cell</mesh_term>
	<mesh_term>Hodgkin Disease</mesh_term>
	<mesh_term>Lymphoma , B-Cell</mesh_term>
	<mesh_term>Lymphoma , Mantle-Cell</mesh_term>
	<mesh_term>Leukemia , Myelogenous , Chronic , BCR-ABL Positive</mesh_term>
	<mesh_term>Lymphoma , B-Cell , Marginal Zone</mesh_term>
	<mesh_term>Mycoses</mesh_term>
	<mesh_term>Mycosis Fungoides</mesh_term>
	<mesh_term>Sezary Syndrome</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Cutaneous</mesh_term>
	<mesh_term>Leukemia , T-Cell</mesh_term>
	<mesh_term>Leukemia-Lymphoma , Adult T-Cell</mesh_term>
	<mesh_term>Leukemia , Hairy Cell</mesh_term>
	<mesh_term>Leukemia , Myeloid , Chronic-Phase</mesh_term>
	<mesh_term>Lymphoma , T-Cell , Peripheral</mesh_term>
	<mesh_term>Waldenstrom Macroglobulinemia</mesh_term>
	<mesh_term>Lymphoma , Large-Cell , Anaplastic</mesh_term>
	<mesh_term>Immunoblastic Lymphadenopathy</mesh_term>
	<mesh_term>Lymphoma , Extranodal NK-T-Cell</mesh_term>
	<mesh_term>Lymphomatoid Granulomatosis</mesh_term>
	<mesh_term>Blast Crisis</mesh_term>
	<mesh_term>Lymphoproliferative Disorders</mesh_term>
	<mesh_term>Leukemia , Myeloid , Accelerated Phase</mesh_term>
	<mesh_term>Leukemia , Large Granular Lymphocytic</mesh_term>
	<mesh_term>Intraocular Lymphoma</mesh_term>
	<criteria>INCLUSION CRITERIA PRIOR TO TRANSPLANT : The clinical trial offer high risk ( defined 3 ) patient hematologic malignancy require stem cell transplant part standard care use match related unrelated donor Patients high risk myeloid lymphoid malignancy stem cell transplant follow American Society Blood Marrow Transplantation ( ASBMT ) criterion , include limited condition list ; criterion apply BEFORE cytoreductive therapy give within 28 day plan conditioning : Refractory acute myelogenous lymphoid leukemia Relapsed acute myelogenous lymphoid leukemia Myelodysplastic syndromes 5 % blast Chronic myelogenous leukemia chronic phase 3 , blast phase presently , second accelerate phase Recurrent refractory malignant lymphoma Hodgkin 's disease less partial response transplant High risk chronic lymphocytic leukemia define response stable disease recent treatment regimen DONORS : Matched relate unrelated donor stem cell transplant ( SCT ) match human leukocyte antigen ( HLA ) A B , C , DRB1 molecular method ; 7 8 match donor acceptable related donor Tcell depletion antithymocyte globulin ( ATG ) ( rabbit horse ) least 30 mg alemtuzumab total condition regimen Immune suppression ; plan posttransplant immune suppression include tacrolimus cyclosporin monotherapy ( i.e. , calcineurin inhibitor CN ) alemtuzumab regimens second immune suppressant ATG treat patient ; agent may use CN intolerance toxicity occur posttransplant Zubrod performance status ( PS ) 02 equivalent Karnofsky PS Eligible allogeneic transplant treat physician ' judgment institutional standard ELIGIBILITY TO RECEIVE DLI POSTTRANSPLANT : Donor lymphocytes available able collect No evidence disease standard morphology ; minimal residual disease molecular evidence disease exclude Absolute neutrophil count &gt; = 500/μl Platelet count &gt; = 20,000/μl without transfusion 7 day Serum glutamic oxaloacetic transaminase ( SGOT ) serum glutamate pyruvate transaminase ( SGPT ) = &lt; 5 x upper limit normal ( ULN ) Bilirubin = &lt; 3 x ULN No evidence grade II high acute GVHD chronic GVHD initiation first DLI No systemic corticosteroid immunosuppressive drug ( topical acceptable ) ; replacement steroid adrenal insufficiency exclude EXCLUSION CRITERIA PRIOR TO TRANSPLANT : Pregnant lactating female Hepatitis B positive viral load prior transplant condition hepatitis C virus Human immune deficiency virus Psychiatric illness may make compliance clinical protocol unmanageable may compromise ability patient give inform consent Creatinine &gt; = 2.0 mg/dL SGOT SGPT &gt; = 5 x ULN ; liver biopsy preferred patient Bilirubin &gt; = 3 x ULN ( unless Gilbert 's syndrome ) Diffusing capacity lung carbon monoxide ( DLCO ) &lt; 50 % correct hemoglobin Left ventricular ejection fraction shorten fraction &lt; 40 % Unlikely able procure additional donor lymphocyte</criteria>
	<gender>All</gender>
	<minimum_age>14 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>July 2016</verification_date>
</DOC>